Home›Trial›NCT04933721
🔬NCT04933721Phase 3ENROLLING BY INVITATION

Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies

Study Summary

This is a phase 3b open-label study providing access to berotralstat for HAE patients who were previously enrolled in berotralstat studies.

Conditions
Hereditary AngioedemaHAE
Interventions / Drugs
berotralstat
View on ClinicalTrials.gov ↗
Sponsor
BCRX
BioCryst Pharmaceuticals
Rare Disease
D36/100
Study Details
Enrollment139 participants
Primary Completion—
Lead SponsorBioCryst Pharmaceuticals
Data Retrieved2026-04-11 04:07:07.352051+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.